Clomipramina 3
Clomipramina 3
22 double-blind, placebo- chronic, handicapping OCD 10-225 mg/d CMP superior to PLB by maximum CMP effect at
controlled, 8-wk active drug of 2: I Y duration (40) flexible patient rating (p<0.05) week 10
period
23 double-blind, placebo- severe OCD without 75 rng/d CMP superior to PLB for low dose, short-active drug
crossover, 4-wk active drug primary or secondary fixed obsessive thoughts but not period
period depression (14) compulsions
24 double-blind. placebo- OCD with at least one 50-300 mg/d CMP superior to PLB by CMP activity in OCD inde-
controlled, 8-wk active drug unsuccessful treatment (12) flexible OCNS rating (p<0.05); no pendent of antidepressant
period difference in HDRS ratings effect
25 double-blind, placebo- patients 10-18 Y with severe up to 3 mg/kg/d CMP superior to PLB by not all subjects benefitted;
crossover, 5-wk active drug OCD (19) to a maximum of OCRS, LOI, NIMH-OC full recovery not obtained;
period 200 mg/d flexible ratings (p<0.05); anxiety relapse upon withdrawal
and depression unchanged
26 double-blind, placebo- OCD of 2: I Y duration, at 50-150 mg/d CMP superior to placebo by 50% response rate, 5 wk to
controlled comparison with least I unsuccessful flexible LOI ratings (p<0.05), NTP effect, relapse upon
NTP (50-150 mg/d) 6-wk treatment (24) not different from CMP or withdrawal
active drug period PLB
27 double-blind comparison treatment-resistant OCD of 75-300 rng/d number and severity of OCD both drugs safe in doses
with AMT 75-300 mg/d, >2 y duration (20) flexible symptoms decreased; administered
4-wk active drug period anxiety and depression
improved on CMP but not
AMT
28 double-blind, placebo- OCD of > I Y duration, pri- 50-300 mg/d CMP superior to CGL and no carryover effect
controlled comparison with mary depression excluded flexible PLB by CPRS-OC, NIMH observed; relapse upon
CGL 30 mg/d, 6-wk active (23) Global, and Compulsive withdrawal
drug period Checklist ratings (p<0.05)
29 double-blind, placebo- OCD of > I Y duration, low 50-300 mg/d CMP superior to DIP by effects seen at 4 and 6 wk
controlled comparison with baseline depression (10) flexible NIMH-OC and CPRS-OC
DIP 50-300 rng/d, 6-wk ratings (p<0.05)
active drug period
30 double-blind, comparison OCD of > 1 Y duration (23) 50-300 mg/d partial improvement with baseline severity greater in
with IMI 50-300 mg/d, flexible both drugs; CMP superior IMI group
12-wk active drug period by SRONS and GEE ratings
(p<0.05)
AMT = amitriptyline; CGL = c1orgiline; CMP = clomipramine; CPRS-OC = Comprehensive Psychopathological Rating Scale-Obsessive Compulsive
Scale; DIP = desipramine; GEE = Global Evaluation of Efficacy; HDRS = Hamilton Depression Rating Scale; IMI = imipramine; LOI = Leyton Obsession-
al Inventory; NIMH-OC = National Institute of Mental Health-Obsessive Compulsive Scale; NTP = nortriptyline; OCD = obsessive-compulsive disorder;
OCNS = Obsessive Compulsive Neurotic Scale; OCRS = Obsessive Compulsive Rating Scale; PLB = placebo; SRONS = Self-Rating Obsessional Neu-
rotic Scale.
nisms of action of monoamine oxidase inhibitor and heterocyclicanti- approachesto diagnosis, treatment,and patho-physiology. Bioi Psychi-
depressantdrugs. J Clin Psychiatry 1985;46:6-22. atry 1987;22:667-87.
4. BERTILSSON L, ASBERG M, THOREN P. Differentialeffect of chlorimi- 30. VOLAVKAJ, NEZIROGW E, YARYURA-TOBIAS JA. Clomipramine and
pramine and nortriptyline on cerebrospinal fluid amine metabolitesof imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;
serotoninand noradrenalin in depression. Eur J Clin Pharmaco11974; 14:83-91.
7:365-8. 31. DEVEAUGH-GEISS J, LANDAU P, KATZ R. Treatment of obsessive com-
5. WHAR J, INSEL TR. Obsessive-compulsive disorder: psychobiological pulsive disorder with clomipramine. Psychiatr Ann 1989;19:97-101.
approachesto diagnosis, treatment, and pathophysiology. Bioi Psychi- 32. JENIKE MA. Psychotherapyof the obsessional patient. In: Jenike MA,
atry 1987;22:667-87. Baer L, Minichiello WE, eds. Obsessive compulsive disorders. Lit-
6. EAJGLE JW, DIETERLE W. The metabolism and pharmacokinetics of clo- tleton, MA: Publishing, 1986:113-24.
mipramine(Anafranilj. J Int MedRes 1973;/:281-95. 33. BAER L, MINICHIELLOWE. Behaviortherapy for obsessive-compulsive
7. EVANS L, BETI J, COX J, DUBOIS J, VANHESS T. The bioavailability of disorder.In: Jenike MA, BaerL, MinichielloWE, eds. Obsessivecom-
oral and parenteral chlorimipramine. Prog Neuropsychopharmacol pulsive disorders. Littleton, MA: Publishing, 1986:45-76.
Bioi Psychiatry 1980;4:293-302. 34. KATZR, LANDAU P, DEVEAUGH-GEISS J, HAKKARAlNENH. Clomipra-
8. BERTILSSON L, BRAITHWAITE R, TYBRING G, GARLE M, BORGA 0. mine in obsessivecompulsivedisorder.Presentedat the Symposiumon
Techniques for plasma protein binding of demethylchlor-imipramine. the Neurophannacology of Serotonin, New York Academy of Sci-
Pharmacopsychiatry 1981;14:100-6. ences, New York,July 10-13, 1989.
9. LUSCOMBE DK. Pharmacokinetics of clomipramine. Br J Clin Pract 35. CARNEY MW, BLACK P. A preliminary investigation of monochlor-
I 979;33(suppl 3):35-50. imipraminein the treatmentof depression.far J Neuropsychiatry 1967;
10. L1NNOILA M, INSEL T, KILTS C, POTTER WZ, MURPHY DL. Plasma 3:179-81.
steady state concentrations of hydroxylated metabolites of clomipra- 36. GORECPO Clomipramine(Anafranil),Tofranil(imipramine)and placebo:
mine. Clin Pharmacol Ther 1982;32:208-1 J. a comparativestudy in relation to electroconvulsivetherapy. J Int Med
II. DUBOIS1P, KUNG W, THEOBAL W, WIRZ B. Measurementof clomipra- Res 1973;I :347-51.
mine, N-desmethylclomipramine, imipramine and dehydro-imipra- 37. HYNES MY. A comparativeclinical trial of oral clomipramine(Anafranil)
mine in biologicalfluids by selectiveion monitoring, and pharmacoki- against amitriptyline.v Int Med Res 1973;1:338-42.
netics of clomipramine. Clin Chem 1976;22:892-7. 38. LINNOILAM, SEPPALA T, MATIILA MJ, VIHKOR, PAKARlNEN A, SKJN-
12. Diagnosticand statisticalmanualof medicaldisorders. 3rded. rev.Wash- NER T. Clomipramineand doxepin in depressive neurosis:plasma lev-
ington, DC: American Psychiatric Association, 1987:245-7. els and therapeutic response. Arch Gen Psychiatry 1980;37:1295-9.
13. ROBINSLN, HELZER JE, WEISSMAN MM, et aI. Lifetime prevalenceof 39. SHAPIROWR. Treatmentof cataplexy with clomipramine. Arch Neurol
specificpsychiatricdisorders in three sites. Arch Gen Psychiatry 1984; 1975;32:653-5.
41:949-58. 40. EATON H. Clomipramine (Anafranil) in the treatment of premature
14. MYERSJK, WEISSMANMM, TISCHLERGL, et aI. Six month prevalence ejaculation. J Int Med Res 1973;1:432-4.
of psychiatric disorders in three communities. Arch Gen Psychiatry 41. CARASSO RL, YEHUDA S, STREIFLER M. Clomipramine and amitryp-
1984;41:959-67. tiline in the treatmentof severe pain.lnt] Neurosci 1979;9:191-4.
15. GOODWIN DW, GUZE SB, ROBINS E. Follow-up studies in obsessional 42. GLOGER S, GRUNHAUS L, BIRMACHERB, TROUDARTT. Treatment of
neurosis. Arch Gen Psychiatry 1969;20: 182-7. spontaneous panic attacks with clomipramine. Am] Psychiatry 1981;
16. FERNANDEZCE, LOPEZ-IBORJ1. Monochlorimipraminein the treatment /38:1215-7.
of psychiatricpatients resistantto other therapies. Actas Luso Esp Neu- 43. SWEDO SE, LEONARD HL, RAPOPORTJL, LENANE MC, GOLDBERGER
rol PsiquiatrGene Afines 1964;26:119-47. EL, CHESLOW DL. A double-blind comparison of clomipramine and
17. CAPSTICK N. Chlorimipramine in obsessional states. Psychosomatics desipramine in the treatment of trichotillomania. N Engl J Med 1989;
1971 ;12:332-5. 32/:497-501.
18. WAXMAN D. A general practitioner's investigationon the use of clomip- 44. BEAUMONT G. Practical considerations on the use of clomipramine
ramine (Anafranil) in obsessional and phobic disorders. An interim (Anafranil)in general practice: an updatedreview.] Int Med Res 1977;
report.v Int Med Res 1973;/:417-20. 5(suppl 1):46-50.
19. WYNDOWEJ, SOLYOML, ANANTH1. Anafranil in obsessive compulsive 45. STERN RS, MARKS 1M, MAWSOND, WSCOMBE D. Clomipramine and
neurosis. CurrTher Res 1975;18:611-7. exposurefor compulsiverituals: U. Plasma levels, side effectsand out-
20. YARYURA-TOBIAS JA, NEZIROGW MS. The action of clorimipraminein come. Br J Psychiatry 1980;/36:161-6.
obsessive compulsive neurosis: a pilot study. Curr Ther Res 1975; 46. ANANTHJ, ASSALIANP, LINKS PS. Intolerableside effects of clomipra-
/7:111-16. mine.v Clin PsychopharmacoI1982;2:215-6.
21. STROEBELCE,SZAREK BL, GWECK Be. Use of clomipramine in treat- 47. SLAREK BL, GOETHE Jw. Orthostatic hypotension as an indicator of
ment of obsessive-compulsive syrnptomatology. J Clin Psychophar- response to clomipramine. Curr Ther Res 1984;36:54-7.
macoI1984;4:98-IOO. 48. Clomipramine for obsessive compulsive disorder. Med Len Drugs Ther
22. MARKS 1M,STERN RS, MAWSOND, COBB J, MCDONALDR. Clomipra- 1988;30: 102-4.
mine and exposurefor obsessivecompulsive rituals: I. Br J Psychiatry 49. ROBINSONML. Epileptic fit after clomipramine(letter). Br J Psychiatry
1980;136: 1-25. 1978;132:525-8.
23. MONTGOMERY SA. Clomipramine in obsessional neurosis: a placebo- 50. OSTERGAARD GZ, PEDERSEN SE. Neonatal effects of maternal clomi-
controlled trial. Pharm Med 1980;1: 189-92. pramine treatment. Pediatrics 1982;69:233-4.
24. MAVISSAKALIAN M, TURNER SM, MJCHELSON L, JACOB R. Tricyclic 51. COWE L, LLOYDDJ, DAWLING S. Neonatalconvulsionscaused by with-
antidepressants in obsessive-compulsive disorder: anti-obsessionalor drawal from maternal clomipramine. Br Med J 1982;284:1837-8.
antidepressantagents? U. Am] Psychiatry 1985;142:572-6. 52. VANSCHEYEN JD, VANKAMMEN DP. Clomipramine-inducedmania in
25. FLAMENTMF, RAPOPORTJL, BERG0, et aI. Clomipraminetreatmentof unipolardepression. Arch Gen Psychiatry 1979;36:560-5.
childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1985; 53. MONTEIROWO,NOSHIRVANI HF,MARKS1M,LELLIOTI PT. Anorgasmia
42:977-83. from clomipramine in obsessive-compulsive disorder: a controlled
26. THOREN P, ASBERGM, CRONHOLMB, JORNESTEDTL, TRASKMAN L. trial. Br J Psychiatry 1987;15/:107-12.
Clomipramine treatment of obsessive-compulsive disorder. I. A con- 54. MCLEANJD, FORSYTHERG, KAPKJNIA. Unusualsideeffectsof clomip-
trolledclinical trial. Arch Gen Psychiatry 1980;37:1281-5. ramine associated with yawning. Can] Psychiatry 1983;28:569-70.
27. ANANTHJ, PECKNOLDJC, VANDENSTEEN N, ENGELSMAN F. Double- 55. FRANCIS AF, WILLIAMS P, WILLIAMS R, LINK J, COLE E, HUGHES D.
blindcomparativestudyof chlorimipramineand amitriptyline in obses- The effect of clomipramine on prolactin levels-pilot studies.
sive neurosis. Prog Neuropsychopharmacol Bioi Psychiatry 1981; PostgradMed J I 976;52(suppl 3):87-91.
5:257-62. 56. ANANDVS. Clomipramine-inducedgalactorrhoeaand amenorrhoea. Br
28. INSELTR, MURPHY DL, COHEN RM, ALTERMANI, KILTSC, LINNOILA ] Psychiatry 1985;147:87-8.
M. Obsessive-compulsivedisorder. A double blind trial of clomipra- 57. SOUHAMJRL, ASHTON CR, LEE-POTIER JP. Agranulocytosis and sys-
mine and clorgyline. Arch Gen Psychiatry 1983;40:605- I I. temic candidiasis following clomipramine therapy. Postgrad Med J
29. WHAR J, INSEL TR. Obsessive-compulsivedisorder: psychobiological 1976;52:472-4.